⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8025014 | 0.69 | CA12 (0.35) | — | |
| SCHEMBL27245995 | 0.69 | ALDH1A1 (0.33) | — | |
| SCHEMBL13811980 | 0.68 | — | — | |
| SCHEMBL8325743 | 0.68 | — | — | |
| SCHEMBL29903184 | 0.68 | — | — | |
| SCHEMBL29909960 | 0.65 | — | — | |
| SCHEMBL12520917 | 0.65 | — | — | |
| SCHEMBL29427881 | 0.64 | GSK3A (0.39) | — | |
| SCHEMBL29899204 | 0.64 | PARP1 (0.34) | — | |
| SCHEMBL8469341 | 0.64 | SIGMAR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240224960-A1 | PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF | PESTELL RICHARD G (US) | 2024-07-11 | — | — | US | disclosed |
| US-20220395553-A1 | CXCR4 ANTAGONIST PEPTIDES | COHBAR, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2021097256-A1 | CXCR4 ANTAGONIST PEPTIDES | COHBAR, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-10952415-B2 | Prostate cancer cell lines, gene signatures and uses thereof | Pestell, Richard G. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-2683643-B1 | PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF | PESTELL RICHARD G (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-1976847-B1 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8759517-B2 | Pyrirnidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| EP-2683643-A2 | PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF | Pestell, Richard G. (US) | 2014-01-15 | — | — | EP | disclosed |
| EP-1418917-A1 | USE OF C-SRC INHIBITORS ALONE OR IN COMBINATION WITH STI571 FOR THE TREATMENT OF LEUKAEMIA | Novartis AG (CH) | 2004-05-19 | — | — | EP | disclosed |
| EP-1416935-A1 | 4-AMINO-6-PHENYL-PYRROLO 2,3-D]PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-05-12 | — | — | EP | disclosed |
| EP-1390369-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| WO-2004005282-A1 | PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003097641-A2 | 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003078404-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003013540-A1 | USE OF C-SRC INHIBITORS ALONE OR IN COMBINATION WITH STI571 FOR THE TREATMENT OF LEUKAEMIA | NOVARTIS AG (CH) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003013541-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002092599-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |